Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

Michael Gibson, C.; Mehran, Roxana; Bode, Christoph; L. Halperin, Jonathan; W.A. Verheugt, Freek; Wildgoose, Peter; C. Birmingham, Mary; Ianus, Juliana; Burton, Paul; van Eickels, Martin; Korjian, Serge; Daaboul, Yazan; Y.H. Lip, Gregory; Cohen, Marc; Husted, Steen; D. Peterson, Eric; A.A. Fox, Keith

doi:10.1056/nejmoa1611594

Public

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

Published in New England Journal of Medicine • Nov 14, 2016

Authors:

C. Michael Gibson

Roxana Mehran

Christoph Bode

Abstract

BACKGROUND: inhibitor and aspirin reduces the risk of thrombosis and stroke but increases the risk of bleeding. The effectiveness and safety of anticoagulation with rivaroxaban plus either one or two antiplatelet agents are uncertain. METHODS: inhibitor for 12 months (group 1), very-low-dose rivarox...

Subject

Conventional PCI

Atrial fibrillation

Cardiology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!